Free shipping on all orders over $ 500


Cat. No. M1757
XL-184 Structure

Cabozantinib, BMS-907351

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 70 In stock
10mg USD 90 In stock
50mg USD 120 In stock
100mg USD 180 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

XL184 is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. MET is a receptor tyrosine kinase that plays key roles in cellular proliferation, migration, and invasion as well as angiogenesis. These biological processes contribute to the transformation, progression, survival and metastasis of cancer cells. The MET pathway is frequently activated in tumors through MET amplification, mutation, and overexpression, as well as through overexpression of its ligand HGF. Expression of VEGF has been observed in a variety of cancers and has been associated with the stimulation and growth of new blood vessels to support the tumor. MET and VEGFR2 are important driving forces in angiogenesis, implicated in the ability of tumors to overcome hypoxia following angiogenesis inhibition.

Customer Product Validations & Biological Datas
Source Pharma Res (2017). Figure 5. XL-184
Method ABCG2 ATPase assay
Cell Lines H460, H460/MX20 cells
Concentrations 10 μM
Incubation Time 72 h
Results As shown in Fig 5, the subcellular distribution of ABCG2 incubated with cabozantinib for 72 hours did not change compared to the cells incubated in the absence of cabozantinib.
Source Pharma Res (2017). Figure 3. XL-184
Method [3H]-MX accumulation and efflux assay
Cell Lines H460 and H460/MX20 cell line
Concentrations 5 μM
Incubation Time 2 h
Results As Shown in Fig 3, incubation of H460 cells with or without 5 μM of cabozantinib did not alter intracellular accumulation of MX. However, in the H460/MX20 cell line, 5 μM cabozantinib could significantly increase the fluorescence of MX inside the cells.
Cell Experiment
Cell lines ST-88, STS26T and MPNST724 cells line
Preparation method Cell growth assays
MTS assays: these were conducted using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega Corp, Madison, WI), per manufacturer's instructions. Drugs were administered at doses and for intervals as indicated. Absorbance was measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells. Colony formation assay: one hundred viable cells per well were plated and allowed to grow in normal medium for 10 days and then stained for 30 min at room temperature with a 6% glutaraldehyde, 0.5% crystal violet solution. Pictures were captured digitally and colonies were counted. All experiments were repeated at a minimum twice for each cell line.
Concentrations 0~10 µ M
Incubation time 48 h
Animal Experiment
Animal models SCID mice bearing STS26T and MPNST724 xenografts
Formulation not mentioned
Dosages 30mg/kg/d
Administration gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 501.51
Formula C28H24FN3O5
CAS Number 849217-68-1
Purity >99%
Solubility DMSO
Storage at -20°C

Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
Bowles DW et al. Drugs Today (Barc). 2011 Nov;47(11):857-68. PMID: 22146228.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM et al. Mol Cancer Ther. 2011 Dec;10(12):2298-308. PMID: 21926191.

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Kurzrock R et al. J Clin Oncol. 2011 Jul 1;29(19):2660-6. PMID: 21606412.

Related c-Met Products

Dihexa is an orally active, blood-brain barrier-permeable angiotensin IV analog, exhibits high affinity binding hepatocyte growth factor (HGF) with a Kd of 65 pM.


NPS-1034 is a dual inhibitor of Axl and MET with IC50 values of 10.3 and 48 nM, respectively.


CEP-40783 (RXDX-106) is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.


Savolitinib (volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.

AMG 337

AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.

Abmole Inhibitor Catalog 2017

Keywords: XL-184, Cabozantinib, BMS-907351 supplier, c-Met, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.